GABAergic inhibition in dual-transmission cholinergic and GABAergic striatal interneurons is abolished in Parkinson disease

N. Lozovaya, S. Eftekhari, R. Cloarec, L. A. Gouty-Colomer, A. Dufour, B. Riffault, M. Billon-Grand, A. Pons-Bennaceur, N. Oumar, N. Burnashev, Y. Ben-Ari () and C. Hammond
Additional contact information
N. Lozovaya: Batiment Beret-Delaage, zone Luminy entreprises
S. Eftekhari: Batiment Beret-Delaage, Zone Luminy Biotech Entreprises
R. Cloarec: Batiment Beret-Delaage, Zone Luminy Biotech Entreprises
L. A. Gouty-Colomer: Batiment Beret-Delaage, Zone Luminy Biotech Entreprises
A. Dufour: Batiment Beret-Delaage, Zone Luminy Biotech Entreprises
B. Riffault: Batiment Beret-Delaage, Zone Luminy Biotech Entreprises
M. Billon-Grand: Batiment Beret-Delaage, Zone Luminy Biotech Entreprises
A. Pons-Bennaceur: INMED, INSERM U901 and Aix-Marseille University
N. Oumar: Batiment Beret-Delaage, zone Luminy entreprises
N. Burnashev: INMED, INSERM U901 and Aix-Marseille University
Y. Ben-Ari: Batiment Beret-Delaage, zone Luminy entreprises
C. Hammond: Batiment Beret-Delaage, zone Luminy entreprises

Nature Communications, 2018, vol. 9, issue 1, 1-14

Abstract: Abstract We report that half striatal cholinergic interneurons are dual transmitter cholinergic and GABAergic interneurons (CGINs) expressing ChAT, GAD65, Lhx7, and Lhx6 mRNAs, labeled with GAD and VGAT, generating monosynaptic dual cholinergic/GABAergic currents and an inhibitory pause response. Dopamine deprivation increases CGINs ongoing activity and abolishes GABAergic inhibition including the cortico-striatal pause because of high [Cl−]i levels. Dopamine deprivation also dramatically increases CGINs dendritic arbors and monosynaptic interconnections probability, suggesting the formation of a dense CGINs network. The NKCC1 chloride importer antagonist bumetanide, which reduces [Cl−]i levels, restores GABAergic inhibition, the cortico-striatal pause-rebound response, and attenuates motor effects of dopamine deprivation. Therefore, most of the striatal cholinergic excitatory drive is balanced by a concomitant powerful GABAergic inhibition that is impaired by dopamine deprivation. The attenuation by bumetanide of cardinal features of Parkinson’s disease paves the way to a novel therapeutic strategy based on a restoration of low [Cl−]i levels and GABAergic inhibition.

Date: 2018
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/s41467-018-03802-y Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:9:y:2018:i:1:d:10.1038_s41467-018-03802-y

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-018-03802-y

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().